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Background: Human tuberculosis (TB), a chronic inflammatory disease is caused by Mycobacterium tuberculosis, a
facultative intramacrophage pathogen. The highly complex interactions between mycobacteria and macrophages
(MΦs), characterized in part by the induction and elaboration of several cytokines including IL-1, IL-6, IL-10, IL-12
p40 and IL-12 p70 are not yet fully understood. The cytokines are known to have important bearing on the
pathogenesis and host defense during TB. We thus studied different patterns of cytokines elaborated by mouse
peritoneal macrophages (PMs) following their interaction with live and heat-killed, virulent and avirulent, and
pathogenic and non-pathogenic mycobacteria, in vitro.
Materials and methods: Pathogenic M. tuberculosis H37Rv (virulent) and M. tuberculosis H37Ra (avirulent), and
non-pathogenic M. smegmatis were grown in complete Middle Brook 7H9 broth. For some experiments, mycobacteria
were heat-killed (80°C; 20 min). The supernatants of cultured PMs, having ingested mycobacteria for 6 h, 24 h, 4 days
and 7 days, were harvested for the quantification of IL-1, IL-6, IL-10, IL-12 p40 and IL-12 p70 by using a multiplex
suspension cytokine array system.
Results: The PMs infected with heat-killed mycobacteria, as compared to their respective live counterparts,
invariably elaborated significantly (p < 0.001) increased (approximately 2–3-fold) amounts of IL-6, at all the
time-points studied, in vitro. Further, PMs infected with M. tuberculosis H37Ra, as compared to M. tuberculosis
H37Rv, elaborated 4–5-fold more (p < 0.001) IL-6. Non-pathogenic M. smegmatis, as compared to pathogenic
M. tuberculosis H37Ra and M. tuberculosis H37Rv, following infection, induced the PMs to elaborate highest
(p < 0.001) amounts of IL-6 at all the time-points studied. Curiously, none of these mycobacteria-infected PMs
elaborated IL-1, IL-10, IL-12 p40 and IL-12 p70, significantly.
Conclusion: IL-6 appears to be the only major cytokine elaborated by mycobacteria-infected PMs, in vitro, and
thus may function as a potent biomarker of mycobacterial infection, either stand-alone or along with other
cytokines.
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Globally, tuberculosis (TB) continues to be a major public
health problem, and is responsible for an estimated 1.4 mil-
lion deaths and 8.7 million new cases every year (World
Health Organization, 2012). TB, caused by Mycobacterium
tuberculosis, a slow-growing facultative pathogen, is a proto-
typical re-emerging infectious disease in the developed
countries, whereas it is a major cause of morbidity and mor-
tality in the developing countries (North and Jung, 2004).* Correspondence: drppsingh2005@gmail.com
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worse due to the emergence of multidrug-resistant (MDR)
and virtually untreatable extensively drug-resistant (XDR)
strains of M. tuberculosis (World Health Organization,
2012; Shah et al., 2007). The emergence and unabated
spread of human-immunodeficiency virus (HIV) among
TB patients has added new formidable dimensions to the
problem of TB. During TB, macrophages (MΦs) are the
first host cells to interact with M. tuberculosis, and func-
tion as the major habitat center for its intracellular multi-
plication and growth. The interaction of MΦs, one of the
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induction and elaboration of several pro-inflammatory
[interleukin-1β (IL-1β), IL-6, IL-12, tumor necrosis factor-α
(TNF-α), granulocyte-macrophage (GM) colony-stimulating
factor (CSF; GM-CSF), granulocyte-CSF (G-CSF)] and anti-
inflammatory cytokines including IL-10. The intricate inter-
play of these cytokines is thought to orchestrate the
induction and progression of an effective innate anti-
mycobacterial immune response.
Immunity and inflammation are intertwined processes.
IL-1, IL-6, IL-12 p40 and IL-12 p70 are known to exert
pro-inflammatory effects. IL-1 has been reported to pro-
tect hosts against various infections, and is involved in
the onset and progression of an acute-phase response
(Dinarello, 1996). Double-knockout (KO) mice, deficient
in both IL-1α and IL-1β, following infection with M. tu-
berculosis H37Rv, have been reported to develop larger
granulomatous lesions (Yamada et al., 2000), whereas IL-1
type 1 receptor knockout mice were highly susceptible,
showed greater mycobacterial load, and developed granu-
lomas with fewer MΦs and lymphocytes, and abundant
granulocytes (Juffermans et al., 2000). IL-6 is a multifunc-
tional cytokine with at least three major reported func-
tions. First, IL-6, together with TNF-α and IL-1β, initiates
early pro-inflammatory responses (Van Snick, 1990), and
is a known inducer of acute-phase proteins (APPs) (Singh
and Kaur, 2005). Second, IL-6 is involved in the promotion
of T-cell and B-cell responses (Van Snick, 1990). Third,
IL-6 participates in hematopoiesis (Van Snick, 1990). IL-6
has also been shown to play a role in the priming of a TB
subunit vaccine (Leal et al., 2001). IL-6 deficient mice have
been reported to be highly susceptible and ultimately suc-
cumbed to TB (Ladel et al., 1997). Additionally, IL-6 has
been reported to be required for interferon-γ (IFN-γ)-in-
duced protection against M. tuberculosis infection in mice
(Saunders et al., 2000). Paradoxically, IL-6 is also known to
promote the intracellular growth of M. avium (Shiratsuchi
et al., 1991), and to inhibit the production of TNF-α and
IL-1β (Schindler et al., 1990). IL-12, known to stimulate the
growth of NK cells and T-cells, enhances the production of
cytokines, and connects innate and adaptive immune re-
sponses against mycobacterial infections (Trinchieri, 1995).
IL-12 has been reported to exert its protective effects in M.
tuberculosis-infected mice, mainly through IFN-γ (Cooper
et al., 1997). Therapeutic effect of transgenic tomato over-
expressing IL-12 has been reported in a murine model of
progressive pulmonary TB (Elías-López et al., 2008). IL-12
receptor deficiency has been reported to be a cause for le-
thality in disseminated MDR adult TB (Tabarsi et al., 2011).
On the other hand, transgenic mice over-expressing IL-10
have been reported to be highly susceptible to M. avium in-
fection, as compared to the Wild-type ones (Feng et al.,
2002). IL-10 has also been thought to be responsible for the
suppression of immune response against TB, andpersistence of a long-term M. tuberculosis infection
(Redford et al., 2011). IL-10 gene polymorphism plays a
major role in susceptibility to or protection against TB
(Ben-Selma et al., 2011). Increased anti-mycobacterial
immunity has been observed in IL-10 deficient mice,
which shows that IL-10 is an inhibitor of early mycobac-
terial clearance (Murray and Young, 1999). The present
studies were undertaken to delineate the elaboration of
IL-1β, IL-6, IL-10, IL-12 p40 and IL-12 p70 by mouse
peritoneal macrophages (PMs) infected with M. tubercu-
losis H37Rv, M. tuberculosis H37Ra and M. smegmatis,
in vitro, in terms of their potential to function as a bio-
marker(s). Our results, for the first time, demonstrate that
IL-6 can be used as a biomarker of mycobacterial infec-
tion, either stand-alone or along with other cytokines.
Materials and methods
Mycobacterial cultures
M. tuberculosis H37Rv, M. tuberculosis H37Ra and M.
smegmatis were grown in complete 7H9 broth (Hi-Media
Laboratories Pvt. Ltd., Mumbai, India) supplemented with
1% glycerol (Hi-Media Laboratories), 0.05% Tween-80
(Sigma Aldrich, St. Louis, MO, USA) and 10% Middlebrook
OADC enrichment (Difco, Sparks, MO, USA). The myco-
bacterial growth was monitored spectrophotometrically.
For use in experiments, a single-cell bacterial suspension
was prepared (by sonication at 20 KHz; 10 s; 10 cycles),
gently agitated, and allowed to stand at room temperature
for 10 min to allow the mycobacterial clumps to settle-
down. The top part of the mycobacterial suspension was
then adjusted to 1 McFarland standard, and diluted in
antibiotic-free Dulbecco modified Eagle’s medium (DMEM;
PAA laboratories GmbH, Austria) containing 2 mM L-
glutamine (PAA laboratories GmbH), 0.01 M HEPES
(Hi-Media laboratories) and 1 × 10-4 M 2-mercaptoethanol
(Sigma Aldrich, St. Louis, MO, USA). To this, 1% heat-
inactivated fetal bovine serum (FBS; PAA laboratories) was
added. In some experiments, heat-killed (at 80°C in a water
bath; 20 min) mycobacteria were used.
Mice
Swiss mice (either sex; 18–20 g), obtained from the Central
Animal Facility of the institute, were maintained at 22–
24°C and 12 h light/dark cycle, with food and water pro-
vided ad libitum. All the experiments were done in ac-
cordance with the guidelines for the care and use of
animals in scientific research, Indian National Science
Academy, New Delhi, as adapted and promulgated by
the Institutional Animal Ethics Committee.
Macrophage culture
Mouse PMs were harvested as described (Kaur et al., 2004).
Briefly, thioglycolate (4% wt/vol., 0.5 ml/mouse, 96 h; Sigma
Aldrich)-elicited mouse peritoneal exudate cell suspension
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4°C; 7 min) and, the cell pellet was re-suspended (2 × 106
cells/well) in the same medium supplemented with 10%
FBS (CDMEM) and adjusted to 1 × 106 cells/ml, and then
2 ml of the cell suspension was transferred to the wells of
sterile 24-well tissue culture plates. The plates were incu-
bated overnight at 37°C in a 5% CO2 incubator for cell ad-
herence, and the non-adherent cells were washed-off with
warm Hank’s balanced salt solution (HBSS). For T-cell re-
moval, the adherent PMs were treated with rabbit anti-
mouse T-cell serum (1:20; 4°C; 1 h), washed (×1) with warm
HBSS and then incubated with rabbit complement (37°C;
1 h). As determined by LAL assay, the DMEM and HBSS
contained < 0.1 ng/ml endotoxin. The PMs were > 96%
pure according to morphologic, phagocytic and non-
specific esterase staining criteria, and were > 98% viable as
judged by trypan blue (Sigma Aldrich) exclusion.
Infection of PMs
For infection, PM monolayers were exposed to both live
and heat-killed M. tuberculosis H37Rv, M. tuberculosis
H37Ra and M. smegmatis (multiplicity-of-infection, 1:10),
separately, at 37°C for 4 h. Later, the extracellular myco-
bacteria were washed (×3)-off by warm HBSS, and 2 ml of
fresh CDMEM was added to each well. The culture plates
were then incubated at 37°C in a 5% CO2 incubator for
6 h, 24 h, 4 days and 7 days. After specific periods of incu-
bation, the PM culture supernatants were harvested, filter
(0.22 μ)-sterilized, and stored frozen (-70°C) until use.
Cytokine quantification
A multiplex cytokine 5-plex kit (IL-1β, IL-6, IL-10, IL-12
p40 and IL-12 p70) was utilized according to the manu-
facturer’s instructions (Bio-Rad, Hercules, CA, USA).
The calibration curves were generated from the recom-
binant cytokine standards with serial dilutions in serum
standard diluent. High and low reference points were in-
cluded to determine cytokine recovery. The assays were
performed in 96-well filter-plates (Bio-Rad). All incuba-
tion steps were performed at room temperature and in
dark to protect the beads from light. In brief, the wells
were pre-wetted with 100 μl of assay buffer, which was
later removed by vacuum suction. The coupled beads (1×)
in the kit were vortexed and then transferred (50 μl) to
each well. The beads were filter-washed (×2) by using
100 μl wash buffer. The appropriate diluted standards,
controls and samples (50 μl each) were then added to each
well, and the filter-plates were shaken on a plate-shaker
first at 1,100 rpm for 30 s and then at 300 rpm for 30 min.
After incubation, the wells were washed (×3) with wash
buffer. The beads in the wells were then incubated with
detection antibodies (25 μl) on a plate-shaker at 300 rpm
for 30 min, and washed (×3) again with 100 μl wash buf-
fer. Fifty μl streptavidin-phytoerythin (1× in assay buffer)was then added to each well, the filter-plates were kept for
10 min, and the wells were washed (×3) with 100 μl wash
buffer. Finally, 125 μl assay buffer was added to each well
and the plates were shaken at 1,100 rpm for 30 s. The
fluorescence intensity of the beads was measured by using
a Bio-plex array reader. Bio-plex manager software with
five-parametric-curve fitting (Bio-Rad technical note 2861
at www.bio-rad.com) was used for data analysis.
Statistical analysis
The data were analyzed by SigmaPlot Statistical Software
11.0. Multiple groups were analyzed by one-way ANOVA
followed by Tukey’s multiple comparison tests, and p <
0.05 was considered significant.
Results
Standard curves for recombinant cytokines
The Standard curves were generated for recombinant
cytokines (IL-1β, IL-6, IL-10, IL-12 p40 and IL-12 p70).
The cytokine-specific single beads (5 different bead pop-
ulations) were identified through sequential gating on
doublet discriminator signal and intrinsic bead dye (red
vs infrared), exclusive of bead aggregates and debris. The
concentration of cytokines was measured as mean fluor-
escence intensity of the streptavidin-PE signal on the
surface of the beads, from a minimum of 50 beads/cyto-
kine. The standards were calculated in duplicate for
eight data-points. The standard curves were then plotted
through a five-parameter logistic curve fitting (Figure 1).
Cytokine elaboration by live mycobacteria-infected PMs,
in vitro
The PMs infected with live M. tuberculosis H37Ra, as com-
pared to those infected with M. tuberculosis H37Rv and M.
smegmatis, invariably, elaborated significantly (p < 0.001)
augmented levels of IL-6 in their culture medium (Figure 2).
Kinetically, the increased IL-6 elaboration could be ob-
served as early as at 6 h, which reached its maximum
(2785.75 ± 438.05 pg/ml) at 24 h, dipped slightly (1904 ±
72.12 pg/ml) on Day 4, and then almost plateaued there-
after till Day 7 (2372 ± 275.77 pg/ml) observed. On the
other hand, IL-6 elaboration by M. tuberculosis H37Rv-
infected PMs, though significantly (p < 0.001) low as com-
pared to that elaborated by M. tuberculosis H37Ra-infected
PMs, could also be observed as early as at 6 h, which
reached its maximum at 24 h (688.25 ± 33.59 pg/ml; nearly
4-fold less as compared to that elaborated by M. tubercu-
losis H37Ra-infected PMs), and then plateaued thereafter
till Day 4 (552.5 ± 19.09 pg/ml) and Day 7 (454.5 ±
16.26 pg/ml) observed. Notably, IL-6 elaboration by the
PMs infected with M. smegmatis, unlike M. tuberculosis
H37Ra and M. tuberculosis H37Rv, could only be observed
as early as at 24 h (427 ± 62.23 pg/ml), reached its max-
imum on Day 4 (830.25 ± 35 pg/ml) and then returned
Figure 1 Standard curves for recombinant cytokines. Data were generated by combining an eight-fold dilution of the various standards
(IL-1β, IL-6, IL-10, IL-12 (p40), IL-12 (p70). The fluorescence intensity (FI) was measured by using the Bio-plex system (Multiplex Suspension Cytokine
Array; Bio-Rad, Hercules, CA, USA). Standard curves were quantified and plotted with Bio-Plex Manager software by a five-parameter
regression formula.
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live mycobacteria induced the PMs for any significant in-
crease in the elaboration of IL-1β, IL-10, IL-12 p40 and
IL-12 p70 (data not shown).
Cytokine elaboration by heat-killed mycobacteria-infected
PMs, in vitro
The PMs infected with both live and heat-killed M. tuber-
culosis H37Ra, separately, at both 6 and 24 h, elaborated
IL-6 in quantities that were not significantly different from
each other; however, on both Day 4 and Day 7, PMs in-
fected with the heat-killed M. tuberculosis H37Ra, asFigure 2 Determination of IL-6 elaborated by PMs infected with live a
non-pathogenic (M. tuberculosis H37Ra and M. smegmatis) mycobactecompared to those infected with the live ones, elaborated
significantly (p < 0.001) higher levels of IL-6 (3375.25 ±
78.84 pg/ml and 3392.5 ± 62.93 pg/ml on Day 4 and Day
7, respectively; Figure 2). Similarly, PMs infected with both
live and heat-killed M. tuberculosis H37Rv, separately,
elaborated IL-6, at both 6 and 24 h, in quantities which
were not significantly different from each other; however,
on both D4 and D7, the heat-killed M. tuberculosis H37Rv
elaborated significantly higher levels of IL-6, as compared
to the live ones. Invariably, M. tuberculosis H37Ra-infected
PMs, as compared to those infected with M. tuberculosis
H37Rv, irrespective of live or heat-killed bacilli, at all thend dead, and pathogenic (M. tuberculosis H37Rv) and
ria, in vitro.
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significantly (p < 0.001) higher. The PMs infected with both
live or heat-killed, M. smegmatis, in contrast to those in-
fected with M. tuberculosis H37Ra and M. tuberculosis
H37Rv, at 6 h, did not elaborate significantly enhanced
levels of IL-6 as compared to that elaborated by the unin-
fected control PMs; however, at 24 h and on both Day 4
and Day 7, the heat-killed M. smegmatis-infected PMs elab-
orated significantly (p < 0.001) higher levels of IL-6 as com-
pared to those infected with the live ones. As in the case of
live mycobacteria, none of these heat-killed mycobacteria,
induced the PMs for any significant increase in the elabor-
ation of IL-1β, IL-10, IL-12 p40 and IL-12 p70 (data not
shown).
Discussion
Our laboratory has been, for over last 15 years, engaged
in molecular studies related to the host-pathogen inter-
action during M. tuberculosis infection. More pointedly,
the identification of biomarkers of mycobacterial infec-
tion, consequent to mycobacteria and MΦ interaction,
in vitro, has been our major focus. In the present stud-
ies, our most important and striking observation has
been that mycobacteria, irrespective of their viability,
virulence and pathogenicity, following their interaction
with the PMs, in vitro, induced them to elaborate sig-
nificantly (p < 0.05) enhanced levels of IL-6 only; the en-
hancement of the elaboration of other studied cytokines
(IL-1β, IL-10, IL-12 p40, and IL-12 p70) was not signifi-
cant. Because a 5-plex cytokine array (IL-1β, IL-6, IL-10,
IL-12p40 and IL-12p70) was used, it is possible that other
cytokines, if up-regulated, would have missed quantifica-
tion. However, literature survey has shown that in most of
such studies including those using human MΦs, mainly
TNF, IFN-γ and GM-CSF are up-regulated, albeit not the
extent we have observed enhanced IL-6 elaboration.
Nevertheless, future studies using larger plex cytokine ar-
rays may shed more light on this point. Therefore, our re-
sults, for the first time, report that IL-6 appears to be the
only cytokine whose elaboration is enhanced significantly
(p < 0.05) following the interaction of PMs with myco-
bacteria, in vitro.
In the recent past, a great significance has been at-
tached to the identification of biomarkers, also known
as biological indicators, of TB. According to Parida and
Kaufmann (2010) a biomarker can be defined as a “char-
acteristic that is objectively measured and evaluated as
an indicator of a physiological or pathological process
or pharmacological response(s) to a therapeutic inter-
vention” (Parida and Kaufmann, 2010). However, so far,
no biomarker(s) has been identified that can be used ef-
fectively for TB. This probably is one good reason that
we still do not have suitable drugs, vaccines and diag-
nostic tests for TB. Therefore, there is an urgent needto have a suitable biomarker or a group of markers (also
called as a biosignature) that is a true statistical reflec-
tion and is pathophysiologically related to the clinical
outcome of TB, with or without therapeutic interven-
tion. In the present study, apparently for the first time,
an effort has been made to project the elaboration of
IL-6, as a sequel to the interaction of PMs with myco-
bacteria, in vitro, as a potential biomarker of mycobac-
terial infection, either stand-alone or along with other
cytokines, which may be developed further as a bio-
marker/biosignature of TB.
The concept of cytokines to function as biomarkers is
well established and has been reviewed recently (Doherty
et al., 2009), and it has been suggested that both IFN-γ
and TNF-α can function as excellent biomarkers for the
clinical assessment of TB, as their expression and elabor-
ation has been thought to have important bearing on the
immunopathogenesis of TB. Additionally, as both of these
cytokines are induced and expressed rapidly early in the
infection, they can be detected and quantified much be-
fore the onset of the symptoms of TB. Because IFN-γ is
induced in a pathogen-specific manner, it thus constitutes
a preferred biomarker. IL-4 mRNA expression has been
reported to increase in healthy individuals who later de-
velop active TB, and decrease soon after the treatment.
Wassie et al. (2008) have reported that in TB patients
mRNA expression for IL-4δ2, an IL-4 antagonistic splice
variant, appeared to be similar to that of IFN-γ. Rhodes
et al. (2007) have reported that there is a strong possibility
that the ratio of the levels of IL-4 and IL-4 δ2 may correl-
ate with the severity of TB, and thus may serve as a true
reflection of the disease. This contention is further sup-
ported by a recent report (Siawaya et al., 2008), which in-
dicates that quick changes in the ratio of IL-4 and IL-4δ2
levels during TB treatment may serve as good indicators
of further treatment outcome. Augmented IL-6 elabor-
ation can occur during various infections or inflammation.
C-reactive protein, an APP, and other markers of inflam-
mation have also been suggested to function as bio-
markers of TB (Doherty et al., 2009). IL-6 is a known
inducer of APPs, and Singh and Kaur (2006) have re-
ported a near parallel increase in both serum amyloid
P-component (SAP), an APP in mice, and IL-6, in M. tu-
berculosis-infected mice. Our results which demonstrate
the elaboration of only IL-6 as the major cytokine following
the interaction of PMs with mycobacteria, in vitro, also
seem to be in consonance with earlier reports (Mattos
et al., 2010; El-Ahmady et al., 1997). Therefore, IL-6 can
be expected to be developed as a potential biomarker
of TB, either stand-alone or along with other
cytokines.
The mechanisms by which M. tuberculosis and M.
smegmatis induce MΦs to elaborate of IL-6 are not yet
properly understood. However, the lipoarabinomannan
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ent of lipopolysaccharide, in a dose-dependent manner,
has been reported to induce MΦs to elaborate IL-6,
in vitro (Zhang et al., 1994). The LAM-induced mycobac-
terial response elements (transcription factors) NF-IL6
and NF-kB on the IL-6 gene, following their binding with
the IL-6 regulatory region, regulate the expression of IL-6
gene (Zhang et al., 1994). A similar molecular mechanism
(s) of IL-6 induction may also be operational in our studies
reported herein.
We have observed that of all the cytokines studied, in-
variably, only IL-6 elaboration was enhanced significantly
(p < 0.05). Though, apparently, there is no explanation for
these observations, the following reports appear support-
ive. Denis (1992) has demonstrated that in tissue culture
medium, which does not support full growth, both human
and mouse rIL-6 function as potent growth factors for
four virulent strains of M. avium; IL-6 was rapidly taken-
up by the mycobacteria through a single receptor species
of 50 nM Kd with approximately 15, 000 receptors/myco-
bacterium. It may just be possible that mycobacteria, in-
cluding M. tuberculosis, may induce the augmented
elaboration of IL-6 to support their own growth. Presently,
our lab is engaged in the generation of more specific evi-
dences to this effect.
The PMs infected with live M. tuberculosis H37Ra, as
compared to those infected with M. tuberculosis H37Rv
and M. smegmatis, invariably, elaborated significantly (p <
0.001) enhanced levels of IL-6. A major difference exists
between phagosomes containing pathogenic and non-
pathogenic mycobacteria. Phosphatidylinositol 3-phosphate
(PI3P), a membrane trafficking regulatory lipid, is essential
for the phagosomal acquisition of lysosomal contents
(Vergne et al., 2005). M. tuberculosis H37Rv secrets a
lipid phosphatase called SapM, which hydrolyzes PI3P
and thus inhibits the fusion of phagosomes with late
endosomes (Saleh and Belisle, 2000). Non-pathogenic
mycobacteria, on the other hand, do not secrete SapM,
and thus no inhibition of the fusion of phagosomes with
late endosomes occurs. Because phagosome-lysosme fu-
sion is known to result in enhanced elaboration of cyto-
kines, it may be the only possible reason or one of the
possible reasons for the augmented elaboration of cyto-
kines by non-pathogenic mycobacteria. Another reason
for the differential elaboration of cytokines by patho-
genic and non-pathogenic mycobacteria may be because
of the reported difference in their LAM structure. LAM
from non-pathogenic mycobacteria is characterized by
its extensive arabinose side-chains, and is an extremely
potent inducer of cytokines; paradoxically, LAM from
pathogenic mycobacterial species, in which short man-
nan segments extensively mask the arabinan side chain,
is approximately 100-fold less potent (Chatterjee et al.,
1992). The differences in the LAM structure have alsobeen associated with the ability of mycobacteria to sur-
vive and replicate within MΦs, and to cause a product-
ive infection. It is thus possible that M. tuberculosis
H37Ra and M. smegmatis may not be able to cause pro-
ductive infections because of the continuous triggering
of the release of cytokines by the MΦs infected with
them. Thus, these infected MΦs acquire bacteriostatic
activity and possibly, other phagocytic cells may accu-
mulate around them, leading to granuloma formation.
The inherent cytotoxicity of M. tuberculosis H37Rv for
MΦs may also be responsible for the diminished elabor-
ation of cytokines (Falcone et al., 1994). As various M.
tuberculosis field isolates are known to differ in their
virulence and pathogenicity, in the present studies we con-
sidered it expedient to include both avirulent and virulent,
and non-pathogenic and pathogenic mycobacteria.
The heat-killed mycobacteria, as compared to their live
counterparts, induced the infected PMs for enhanced
elaboration of IL-6. The live mycobacteria are known to
inhibit phagosome-lysosome fusion, whereas heat-killed
ones do not (Barker et al., 1997), possibly because of the
enhanced secretion of sulphatides by live mycobacteria
as compared to the heat-killed bacilli (Gordon et al.,
1980). Further, PI3P is known to be retained on the pha-
gosomes which contain heat-killed mycobacteria, but is
continuously eliminated from those having live bacilli
(Vergne et al., 2005). The ability of the heat-killed myco-
bacteria to induce more cytokines may also partially reflect
the loss of direct cytotoxic effect produced by the viable
mycobacteria on infected MΦs (Falcone et al., 1994).
Higher IL-6 production by heat-killed mycobacteria may
simply reflect that once killed, these mycobacteria may lose
partly or completely some of their heat-labile virulence
components, and thus may allow greater phagosome-
lysosme fusion in infected MΦs.
The human relevance of these studies remains an im-
portant point to ponder. Apparently, there is no specific
experimental or clinical evidence(s) to suggest the ex-
trapolation of the results of cytokine elaboration, espe-
cially IL-6, following murine MΦ and mycobacteria
interaction, in vitro, to human situation. However, there
are several reports of the interaction of human MΦs
and mycobacteria (Beltan et al., 2000; Blanchard et al.,
1991), which show results similar to those reported
herein. Therefore, it seems plausible to objectively ex-
trapolate the results of this study to humans both for
clinical and latent TB, albeit after expedient extended
studies, both in murine and human systems. Neverthe-
less, the extrapolation of results generated in vitro using
an isolated population of cells may just be a gross over-
simplification of the events occurring in vivo, and thus
may require a more complex culture system or a suit-
able animal model, which should mimic situation in hu-
man TB patients, as closely as possible. Additionally,
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make these studies applicable to humans.
In conclusion, our results demonstrate that the inter-
action of PMs with mycobacteria, in vitro, invariably, en-
sued in the augmented elaboration of IL-6 only, and thus, it
may be used as a potential biomarker (stand-alone) or as a
biosignature (along with other cytokines), of mycobacterial
infection. Such a biomarker/biosignature is warranted to
aid in the detection of mycobacterial infection, and also,
possibly, to give a fillip to the faster progression of the po-
tential anti-TB drugs presently stagnating in the clinical
trial pipe-line, albeit after due caution and skepticism.
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